The criteria for mice to reach the study endpoint included either >80% CD19+/CD45+ cells in the blood, 20% weight loss, and/or reduced physical mobility due to leukemia progression or potential drug toxicity as described [28, 29, 63]. This evidence concerns the gene PTPRC and leukemia.